A trial looking at treatment for children and young people with kidney cancer, including Wilms' tumour (SIOP WT 2001)
Please note this trial is no longer recruiting patients.
This trial is trying to improve treatment for children and young people with kidney cancer, including a type of kidney cancer called Wilms' tumour.
This trial is for children and young people up to and including the age of 18. We use the term ‘you’ in this summary, but of course if you are a parent, we are referring to your child.
Wilms’ tumour (nephroblastoma) is a type of kidney cancer that affects children. It is cancer of cells in the kidney called nephroblasts. It is a rare cancer that affects about 1 in 10,000 children.
Wilms’ tumours are usually treated with chemotherapy and surgery, and sometimes radiotherapy. But doctors wonder if they may be giving more chemotherapy than is necessary for certain types of Wilms' tumours. This extra treatment may be causing side effects but not treating the cancer.
This trial will recruit children with Wilms’ tumour and some other types of kidney cancer. The aim is to help doctors understand more about kidney cancer in children.
Recruitment
Phase
Who can enter
You can enter this trial if you
- Have been diagnosed with kidney cancer, including Wilms’ tumour
- Are aged 0 to 18 years
- Are fit enough to have chemotherapy and to follow the recommended treatment
Trial design
The treatment you have will depend on the stage of your cancer, and on whether you have low risk, medium risk or high risk Wilms’ tumour. The doctors will look at your Wilms’ tumour cells under a microscope to decide what ‘risk’ it is.
You will have had chemotherapy followed by an operation to remove as much of the cancer as possible. The following information is about the treatment you have after surgery.
Stage 1 Wilms’ tumour
- If you have low risk stage 1 Wilms’ tumour, you will not have any more treatment after surgery
- If you have medium risk stage 1 Wilms’ tumour, you have a short course of dactinomycin (Actinomycin D) and vincristine chemotherapy (AV-1)
- If you have high risk stage 1 Wilms’ tumour, you will have dactinomycin, vincristine and doxorubicin (Adriamycin) chemotherapy (AVD)
Stage 2 and 3 Wilms’ tumour
If you have stage 2 or 3 low risk Wilms’ tumour, you have dactinomycin and vincristine chemotherapy (AV-2).
When the trial started, if you had stage 2 or 3 medium risk Wilms’ tumour you would have been put into one of two treatment groups by a computer. This is called randomisation. You would have either had standard treatment - dactinomycin, vincristine and doxorubicin (AVD), or reduced treatment - dactinomycin and vincristine, but no doxorubicin (AV-2).
But this randomisation finished in 2009. Everybody joining the trial after that who had stage 2 or 3 medium risk Wilms' tumour had AVD.
If you have stage 2 or 3 high risk Wilms’ tumour, you have etoposide (VP16), carboplatin, cyclophosphamide and doxorubicin (the ‘high risk regimen’). You also have radiotherapy to your abdomen. All children with stage 3 Wilms' tumour are recommended to have radiotherapy to their abdomen.
Stage 4 Wilms’ tumour
If you have stage 4 Wilms’ tumour, this means the cancer has spread to another part of your body (metastasised). The treatment you have depends on how well the chemotherapy you had before your operation worked.
- If the chemotherapy worked well, or the cancer spread was completely removed during surgery, you will have dactinomycin, vincristine and doxorubicin chemotherapy (AVD). You also have radiotherapy to your abdomen after chemotherapy
- If your cancer spread did not disappear completely with chemotherapy or could not be removed, you have etoposide (VP16), carboplatin, cyclophosphamide and doxorubicin chemotherapy (the ‘high risk regimen’). You may also have radiotherapy to your abdomen after chemotherapy
- If you have stage 4 high risk Wilms’ tumour and the cancer spread could not be removed with surgery, you have etoposide, carboplatin, cyclophosphamide and doxorubicin chemotherapy (the ‘high risk regimen’). You will then have radiotherapy to your lungs, and possibly radiotherapy to your abdomen.
All stages
You have chemotherapy for between 4 weeks and 8 months depending on what stage and risk your Wilms’ tumour is. Your doctor will tell you in more detail about the treatment you have.
If you have radiotherapy, you have between 8 and 14 treatments (fractions), depending on your age and cancer. Again, your doctor will tell you more about this. You have radiotherapy once a day, Monday to Friday.
The doctors may ask if they can keep a sample of your cancer and a blood sample. If you agree, these samples will be stored and used in future research to help doctors understand more about kidney cancer. You do not have to agree to this part of the trial if you don't want to.
Hospital visits
You will see the doctors and have some tests before taking part in this trial. The tests include
- A biopsy to confirm you have Wilms’ tumour or another type of kidney tumour
- Blood tests
- A physical examination
- An ultrasound of their abdomen
- A chest X-ray
- A heart function test (ECHO)
- Possibly a CT scan
All the chemotherapy drugs in this trial are given through a drip into a vein. If you have the ‘high risk regimen’ you will stay in hospital for chemotherapy. If you have one of the other combinations of chemotherapy, you have your treatment as an outpatient. You will also have radiotherapy as an outpatient.
After treatment you will see the doctors regularly. How often and for how long will depend on the treatment you have, and on how well the treatment works.
Side effects
All chemotherapy drugs have some side effects. The most common side effects are
- A drop in blood cells causing an increased risk of infection, bleeding problems, tiredness and breathlessness
- Feeling or being sick
- Diarrhoea
- Constipation
- Hair loss
- Reduced fertility
There is more information about the side effects of dactinomycin, vincristine, doxorubicin, carboplatin, cyclophosphamide, etoposide on CancerHelp UK.
Location of trial
CLOSEDFor more information
Cancer Research UK
Angel Building
407 St John Street
London
EC1V 4AD
Tel: 0808 800 4040
Email: cancer.info@cancer.org.uk
Please note: we cannot help you to join a specific trial. Unless we state otherwise in this trial summary, you must go through your own doctor.






